Literature DB >> 21636704

Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials.

Michael Weller.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21636704      PMCID： PMC3107105          DOI： 10.1093/neuonc/nor065

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  Jeffrey S Wefel; Timothy Cloughesy; James L Zazzali; Maoxia Zheng; Michael Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Asha Das; Henry S Friedman
Journal:  Neuro Oncol       Date:  2011-05-09       Impact factor: 12.300

3.  Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

Authors:  Christina A Meyers; Kenneth R Hess
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300
  3 in total
  4 in total

1.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

2.  Cognitive dysfunction in patients with brain metastases: influences on caregiver resilience and coping.

Authors:  Marlon Garzo Saria; Natasia Courchesne; Lorraine Evangelista; Joshua Carter; Daniel A MacManus; Mary Kay Gorman; Adeline M Nyamathi; Linda R Phillips; David Piccioni; Santosh Kesari; Sally Maliski
Journal:  Support Care Cancer       Date:  2016-12-05       Impact factor: 3.603

3.  Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial.

Authors:  Bolin Liu; Shujuan Liu; Yuan Wang; Dan Lu; Lei Chen; Tao Zheng; Tao Ma; Yufu Zhang; Guodong Gao; Yan Qu; Shiming He
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

4.  Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.

Authors:  Jay-Jiguang Zhu; Petya Demireva; Andrew A Kanner; Susan Pannullo; Maximilian Mehdorn; Nicholas Avgeropoulos; Andrea Salmaggi; Antonio Silvani; Samuel Goldlust; Carlos David; Alexandra Benouaich-Amiel
Journal:  J Neurooncol       Date:  2017-08-28       Impact factor: 4.130
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.